Oxford University facility is a part of the division of medical sciences, and managed by the department of medicine. It is an MHRA licensed facility for the Good Manufacturing Practice (GMP) manufacture of a range of biologicals, but its main activity over the last decade has been manufacture of clinical grade investigational vaccines. It supports a wide range of vaccine development programs at Oxford University, several of which have been supported in part by European Commission funding. The aim is to provide the link between academic research and clinical drug development, to allow all our collaborators to make rapid progress into clinical trials. GMP manufacturing facility enables to meet the special demands for phase I/II clinical trials of novel biotech products within the academic and commercial sectors and to deliver effective short term treatments to the clinic providing long term benefits to the patient.